GenAssist Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2020

Location

Suzhou Jiangsu China

Primary Industry

Biotechnology

About

Based in Suzhou, China and established in 2020, GenAssist operates as a biotechnology company that engages in research and development of gene editing drug. The founder of the company, He Chunyan, PhD in Immunology from Shanghai Jiaotong University, worked in Fosun Group, Tasly Group, Sunshine Insurance and other companies. The CSO of the company, Dr. Xing Chang, works as an associate professor at Westlake University. The company specializes in the development of therapeutic drugs for neuromuscular diseases bases on TAM base editing technology platform. The company's first product is for Duchenne Muscular Dystrophy (DMD) series of gene mutation diseases. The company's product pipeline can be used to treat Duchenne muscular dystrophy.

Current Investors

Redhill Capital, Sequoia Capital, Zhongxin Suzhou Industrial Park Venture Investment

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development

Website

www.genassisttx.com

Verticals

HealthTech, Manufacturing

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.